Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension (CTAD 2026) - Sep 26, 2026 - Abstract #OC6; Pres time: Nov 16, 2026; 06:00 PM - 06:15 PM; No abstract available
Clinical • Alzheimer's Disease • CNS Disorders
|
|
Christopher VAN DYCK1; David LI2; Michio KANEKIYO2; Shobha DHADDA2; Michelle GEE3; Steven HERSCH2; Michael IRIZARRY2; Lynn KRAMER2
|